Your session is about to expire
← Back to Search
Biktarvy After Kidney Transplant for HIV
Study Summary
This trial will test a new HIV drug, Biktarvy, to see if it is safe and effective. People with HIV who have had a kidney transplant will be switched from their current medication to Biktarvy. The trial will last 48 weeks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently being treated with Biktarvy for HIV.I have had a kidney transplant.I am at least 18 years old.I am currently taking dofetilide or rifampin.My HIV infection has been under control for at least 3 months.You are currently pregnant or breastfeeding.I am HIV positive.I am allergic to one or more drugs in Biktarvy.
- Group 1: Biktarvy
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what ailment is BIKTARVY 50Mg-200Mg-25Mg Tablet typically prescribed?
"BIKTARVY 50Mg-200Mg-25Mg Tablet is primarily used as an anti-retroviral agent but can also be prescribed to treat HIV type 1, those with no resistance to darunavir and individuals who have never been treated before."
Are there any open vacancies for participants in this experiment?
"Clinicaltrials.gov states that this clinical trial is currently in the recruitment phase, which began on November 9th 2020 and was last updated August 1st 2022."
Has any other research been conducted around the effects of BIKTARVY 50Mg-200Mg-25Mg Tablet?
"Currently, there are 98 studies being conducted on BIKTARVY 50Mg-200Mg-25Mg Tablet with 22 trials in the final stage. Most of these clinical trials take place in Boylston, Massachusetts but can also be found at 1610 different medical sites around the world."
How many participants are currently registered in this clinical trial?
"Correct. Details hosted on clinicaltrials.gov demonstrate that this medical trial, which was initially posted on November 9th 2020, is recruiting patients at present. A total of 18 individuals need to be enlisted from a single medical centre."
Has the BIKTARVY 50Mg-200Mg-25Mg Tablet been sanctioned by the United States Food and Drug Administration?
"As this is a Phase 4 trial, with approval from the regulatory authorities, BIKTARVY 50Mg-200Mg-25Mg Tablet receives an overall safety rating of 3."
Share this study with friends
Copy Link
Messenger